NCT02367482Completed
Tryptophan Metabolism in Human Brain Tumors-Novocure
Tryptophan Metabolism in Human Brain Tumors: For Patients Whose Clinical Treatment Includes NovoTTF
Source: ClinicalTrials.gov · Last updated 20 Mar 2025
Brief summary (registry, in English)
In this research study, we will track the build-up of tryptophan, a radioactive tracer, in the brain using positron emission tomography (PET) scanning. Tryptophan, in its natural state, is an amino acid (one of the building blocks of proteins) that is normally present in the brain, and is used by the brain cells to create various other compounds. This process is altered in the presence of a brain tumor. By using a form of tryptophan marked with a small amount of radiation, we will be able to track this process during the course of the PET scan. This research will help determine if AMT PET is a useful method to recognize and differentiate between various types of brain tumors. In addition, to study the mechanisms of altered tryptophan uptake in the tumor and brain, we will also measure tryptophan levels and related molecules in your blood (obtained as a part of the PET procedure) and tumor tissue (in case you will have surgery to remove the tumor). This will help us to find new approaches to treat brain tumors in the future by altering abnormal tryptophan metabolism.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 20 (actual)
- First submitted
- 12 Feb 2015
- Start date
- 1 Jul 2014
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Wayne State University
- Diseases
- Glioblastoma
- NCT number
- NCT02367482
What you commit to
- Study type: Observational
- Participants enrolled: 20
- From 1 Jul 2014 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Resective surgery within 2 months prior to the initial AMT-PET scan (acute/subacute post-surgical inflammatory changes may cause false positive increased uptake on AMT-PET).
- Positive pregnancy test (because of radiation involved in PET scanning).
Other
- Severe increased intracranial pressure, status epilepticus, or other severe complications of the tumor, requiring emergency or urgent intervention.
Who the study is looking for
- Clinical and MRI diagnosis of recurrent GBM.
- Age ≥22 years.
- Patient agrees to NovoTTF treatment but has not started treatment yet.
- Patient agrees to undergo a baseline and a follow-up AMT-PET scan during NovoTTF treatment.
- Patient able to provide informed consent.
Age in the registry: 22 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wayne State University Coordinator of this site? Confirm its status | Detroit | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.